Newsroom
Pharmaceutical manufacturer Remedica Limited has initiated a voluntary recall of specific batches of its prescription drug Remethan 100mg prolonged-release tablets. The company decided to remove the affected inventory from circulation as a preventive measure after routine stability studies revealed results that fell outside established product specifications.
Company officials clarified that the recall is strictly precautionary and that patients face no immediate health risks at this stage of the investigation. However, individuals currently taking this medication are advised to contact their treating physician or pharmacist to discuss alternative treatment options and ensure their therapy continues without interruption.
Remethan 100mg is a prescription-only non-steroidal anti-inflammatory drug, or NSAID. Doctors frequently prescribe it to manage pain, swelling, and inflammation caused by muscle, tendon, and joint conditions such as tendinitis, rheumatoid arthritis, fractures, and dislocations. It is also commonly used to relieve discomfort following minor surgical and dental procedures.
The recall affects specific batches with expiration dates stretching from September 2026 through November 2030. According to company data, the remaining active market stock from the affected pool is likely restricted to batches 116856, 122934, and 127806.
Remedica indicated that further announcements or additional measures may follow as the investigation into the test results continues. The manufacturer maintained that protecting patient safety and health remains its primary priority throughout this process.
